

Andrea Anichini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/46270/publications.pdf>

Version: 2024-02-01

144
papers

9,055
citations

38742

50
h-index

45317

90
g-index

152
all docs

152
docs citations

152
times ranked

13488
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. <i>Cancer Cell</i> , 2013, 23, 249-262.	16.8	721
2	Interleukin-12: Biological Properties and Clinical Application. <i>Clinical Cancer Research</i> , 2007, 13, 4677-4685.	7.0	517
3	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3353-3360.	1.6	474
4	Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?. <i>Journal of the National Cancer Institute</i> , 2002, 94, 805-818.	6.3	381
5	Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€“small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999.	7.0	315
6	NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. <i>Journal of Clinical Investigation</i> , 2009, 119, 1251-1263.	8.2	313
7	Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. <i>Immunological Reviews</i> , 2002, 188, 97-113.	6.0	246
8	BRAF alterations are associated with complex mutational profiles in malignant melanoma. <i>Oncogene</i> , 2004, 23, 5968-5977.	5.9	189
9	An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (CtI)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific CtIs but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions. <i>Journal of Experimental Medicine</i> , 1999, 190, 651-668.	8.5	186
10	Targeting Heat Shock Proteins on Cancer Cells:Â Selection, Characterization, and Cell-Penetrating Properties of a Peptidic GRP78 Ligandâ€“. <i>Biochemistry</i> , 2006, 45, 9434-9444.	2.5	172
11	Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.. <i>Journal of Experimental Medicine</i> , 1993, 177, 989-998.	8.5	166
12	Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. <i>Oncogene</i> , 2006, 25, 3357-3364.	5.9	157
13	Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients. <i>Cancer Research</i> , 2009, 69, 7338-7346.	0.9	157
14	Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. <i>Cancer Research</i> , 2003, 63, 2535-45.	0.9	142
15	Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage. <i>Journal of Experimental Medicine</i> , 1998, 188, 1005-1016.	8.5	131
16	The Î±3Î²1 Integrin Is Involved in Melanoma Cell Migration and Invasion. <i>Experimental Cell Research</i> , 1995, 219, 233-242.	2.6	126
17	Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase. <i>Journal of Investigative Dermatology</i> , 2011, 131, 2448-2457.	0.7	122
18	Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells. <i>Clinical Cancer Research</i> , 2009, 15, 5852-5860.	7.0	120

#	ARTICLE	IF	CITATIONS
19	Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. <i>Nature Communications</i> , 2014, 5, 5639.	12.8	109
20	Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2479-2485.	1.6	103
21	Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma. <i>International Journal of Cancer</i> , 1985, 35, 683-689.	5.1	102
22	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.	1.4	99
23	Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination. <i>Clinical Cancer Research</i> , 2004, 10, 5381-5390.	7.0	98
24	Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 5674-5678.	7.1	95
25	Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. <i>Cell Cycle</i> , 2011, 10, 3346-3358.	2.6	93
26	T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.. <i>Journal of Experimental Medicine</i> , 1993, 178, 1231-1246.	8.5	92
27	Immune Escape Mechanisms in Non Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3605.	3.7	92
28	Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins. <i>International Journal of Cancer</i> , 1991, 47, 551-559.	5.1	89
29	Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations. <i>Neoplasia</i> , 2009, 11, 720-W6.	5.3	87
30	Clonal analysis of the cytolytic T-cell response to human tumors. <i>Trends in Immunology</i> , 1987, 8, 385-389.	7.5	86
31	Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. comparison with anti-proliferative activity by RIL1- $\hat{1}^2$, RTNF- $\hat{1}\pm$, RIFN- $\hat{1}^3$, RIL4 and their combinations. <i>International Journal of Cancer</i> , 1990, 45, 334-341.	5.1	81
32	Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity. <i>Cancer Research</i> , 2006, 66, 6503-6511.	0.9	81
33	Cellular Immune Response Against Autologous Human Malignant Melanoma: Are In Vitro Studies Providing a Framework for a More Effective Immunotherapy?. <i>Journal of the National Cancer Institute</i> , 1990, 82, 361-370.	6.3	77
34	Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of icam-1 phenotype, vla profile and invasive ability. <i>International Journal of Cancer</i> , 1990, 46, 508-515.	5.1	74
35	Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. <i>British Journal of Cancer</i> , 2010, 102, 1707-1716.	6.4	70
36	Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy. <i>Clinical Cancer Research</i> , 2006, 12, 5023-5032.	7.0	64

#	ARTICLE	IF	CITATIONS
37	The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 855-64.	4.2	63
38	The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. <i>Haematologica</i> , 2008, 93, 1523-1534.	3.5	63
39	Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. <i>Journal of Neuro-Oncology</i> , 2014, 118, 305-312.	2.9	61
40	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7351-7362.	7.0	61
41	Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1. <i>Cancer Research</i> , 2007, 67, 4271-4277.	0.9	59
42	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. <i>Oncolmmunology</i> , 2017, 6, e1261242.	4.6	59
43	Heme catabolism by tumor-associated macrophages controls metastasis formation. <i>Nature Immunology</i> , 2021, 22, 595-606.	14.5	59
44	Apoptosis Protease Activator Protein-1 Expression Is Dispensable for Response of Human Melanoma Cells to Distinct Proapoptotic Agents. <i>Cancer Research</i> , 2004, 64, 7386-7394.	0.9	58
45	Association of Antigen-Processing Machinery and HLA Antigen Phenotype of Melanoma Cells with Survival in American Joint Committee on Cancer Stage III and IV Melanoma Patients. <i>Cancer Research</i> , 2006, 66, 6405-6411.	0.9	56
46	Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. <i>Clinical Cancer Research</i> , 2010, 16, 5862-5872.	7.0	56
47	Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. <i>Oncotarget</i> , 2015, 6, 2779-2793.	1.8	56
48	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012, 90, 667-679.	3.9	54
49	Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones.. <i>Journal of Experimental Medicine</i> , 1986, 163, 215-220.	8.5	53
50	Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles. <i>Cancer Research</i> , 2005, 65, 3428-3436.	0.9	53
51	Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma. <i>Cancer Research</i> , 2010, 70, 8378-8387.	0.9	52
52	Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.. <i>Journal of Clinical Investigation</i> , 1997, 99, 710-717.	8.2	51
53	Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2017, 77, 851-861.	0.9	49
54	Monocyte-derived dendritic cells and monocytes migrate to HIV-Tat RGD and basic peptides. <i>Aids</i> , 1998, 12, 261-268.	2.2	48

#	ARTICLE	IF	CITATIONS
55	Immunotherapy of melanoma. <i>Seminars in Cancer Biology</i> , 2003, 13, 391-400.	9.6	48
56	BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2014, 28, 1861-1871.	7.2	48
57	Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: Limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. <i>International Journal of Cancer</i> , 1994, 58, 330-339.	5.1	46
58	Differential patterns of HOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis. , 1996, 66, 692-697.		45
59	Immunological and pathobiological roles of fibulin-1 in breast cancer. <i>Oncogene</i> , 2004, 23, 2153-2160.	5.9	45
60	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. <i>Oncotarget</i> , 2016, 7, 3947-3965.	1.8	45
61	Interleukin-Gene-Transduced Human Melanoma Cells Efficiently Stimulate MHC-Unrestricted and MHC-Restricted Autologous Lymphocytes. <i>Human Gene Therapy</i> , 1994, 5, 1139-1150.	2.7	44
62	Differentiation of CD8+ T Cells from Tumor-Invaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common β -Chain Cytokines. <i>Journal of Immunology</i> , 2003, 171, 2134-2141.	0.8	44
63	NFATc2 is an intrinsic regulator of melanoma dedifferentiation. <i>Oncogene</i> , 2016, 35, 2862-2872.	5.9	43
64	NFATc2 Is a Potential Therapeutic Target in Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2652-2660.	0.7	41
65	EGFR/MEK/ERK/CDK5-dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells. <i>Cell Death and Disease</i> , 2013, 4, e815-e815.	6.3	39
66	AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. <i>Melanoma Research</i> , 2012, 22, 341-350.	1.2	38
67	A microcalorimetric study of the macrocyclic effect. Enthalpies of formation of copper(II) and zinc(II) complexes with some tetra-aza macrocyclic ligands in aqueous solution. <i>Journal of the Chemical Society Dalton Transactions</i> , 1978, , 577.	1.1	37
68	APAF-1 signaling in human melanoma. <i>Cancer Letters</i> , 2006, 238, 168-179.	7.2	37
69	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. <i>Oncotarget</i> , 2015, 6, 5118-5133.	1.8	37
70	Phase II study of sorafenib in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 108-119.	2.5	36
71	The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1011-1022.	4.2	36
72	An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells. <i>Oncogene</i> , 2019, 38, 4384-4396.	5.9	36

#	ARTICLE	IF	CITATIONS
73	Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon β . <i>International Journal of Cancer</i> , 1986, 38, 505-511.	5.1	35
74	Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review). <i>International Journal of Oncology</i> , 2014, 45, 929-949.	3.3	34
75	Tumor cell receptor engagement and tumor ICAM-1 upregulation are required to bypass low susceptibility of melanoma cells to autologous CTL-mediated lysis. <i>International Journal of Cancer</i> , 1993, 53, 994-1001.	5.1	33
76	Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. <i>Clinical Cancer Research</i> , 2014, 20, 5641-5651.	7.0	31
77	HLA class I downregulation is associated with enhanced NK cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. <i>European Journal of Immunology</i> , 2016, 46, 409-419.	2.9	31
78	Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: Role of ICAM-1 defined by antibody blocking and gene transfer. <i>European Journal of Immunology</i> , 1992, 22, 2255-2260.	2.9	30
79	HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. <i>Journal of Cellular Physiology</i> , 2005, 205, 10-18.	4.1	30
80	Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. <i>BMC Cancer</i> , 2014, 14, 560.	2.6	30
81	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 112.	3.7	30
82	Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage. <i>Clinical Cancer Research</i> , 2009, 15, 4085-4094.	7.0	29
83	Microfluidic Devices Modulate Tumor Cell Line Susceptibility to NK Cell Recognition. <i>Small</i> , 2012, 8, 2886-2894.	10.0	29
84	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroenteropancreatic neuroendocrine neoplasms. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 217-226.	3.0	29
85	Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways. <i>Clinical Cancer Research</i> , 2012, 18, 3316-3327.	7.0	27
86	Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2013, 27, 1677-1687.	7.2	26
87	Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. <i>Cancer Research</i> , 2005, 65, 632-40.	0.9	26
88	Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. <i>International Immunology</i> , 2009, 21, 257-268.	4.0	25
89	Multiple sub-sets of Cd4+ and Cd8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. <i>International Journal of Cancer</i> , 1994, 57, 56-62.	5.1	24
90	Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells. <i>Cancer and Metastasis Reviews</i> , 1985, 4, 7-26.	5.9	22

#	ARTICLE	IF	CITATIONS
91	Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells TransducedEx Vivowith a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial. Human Gene Therapy, 2003, 14, 1347-1360.	2.7	22
92	T cell infiltration and prognosis in HCC patients. Journal of Hepatology, 2006, 45, 178-181.	3.7	22
93	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. Clinical Genitourinary Cancer, 2016, 14, 261-264.e4.	1.9	22
94	Clonal analysis of T lymphocyte response to an isolated class I disparity. Human Immunology, 1983, 8, 195-206.	2.4	21
95	Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2941-2945.	7.1	20
96	Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. Cell Death and Disease, 2014, 5, e1434-e1434.	6.3	20
97	Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. Journal of Experimental and Clinical Cancer Research, 2018, 37, 278.	8.6	19
98	High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition. Cancer Immunology, Immunotherapy, 1999, 48, 39-46.	4.2	18
99	Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex. British Journal of Haematology, 2000, 111, 344-350.	2.5	18
100	Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma. International Journal of Cancer, 1988, 42, 239-245.	5.1	17
101	T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: Evidence with a single T cell clone. Cancer Immunology, Immunotherapy, 1990, 32, 13-21.	4.2	17
102	Human Melanocytes and Melanomas Express Novel mRNA Isoforms of the Tyrosinase-Related Protein-2/DOPAchrome Tautomerase Gene: Molecular and Functional Characterization. Journal of Investigative Dermatology, 2000, 115, 48-56.	0.7	17
103	Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. MAbs, 2018, 10, 1084-1097.	5.2	17
104	Calorimetric determination of macrocyclic enthalpy. Copper(II) and zinc(II) complexes with 1,4,8,11-tetra-azacyclotetradecane. Journal of the Chemical Society Chemical Communications, 1977, , 244.	2.0	16
105	Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with ¹³ c cytokines. Blood, 2006, 107, 602-609.	1.4	15
106	Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.. Journal of Clinical Investigation, 1992, 90, 1093-1099.	8.2	15
107	Interaction with fibronectin regulates cytokine gene expression in human melanoma cells. , 1996, 66, 110-116.		14
108	IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain-Restricted B-Cell Non-Hodgkin Lymphomas. Clinical Cancer Research, 2012, 18, 4080-4091.	7.0	14

#	ARTICLE	IF	CITATIONS
109	Thermodynamic and electronic and electron spin resonance spectroscopic investigation of the co-ordinating properties of 4-azaoctane-1,8-diamine (spermidine) in aqueous solution. <i>Journal of the Chemical Society Dalton Transactions</i> , 1977, , 2224.	1.1	13
110	Melanoma cell lysis by human CTL clones: Differential involvement of T3, T8 and HLA antigens. <i>International Journal of Cancer</i> , 1987, 39, 689-694.	5.1	13
111	Analysis of human class II antigens by cloned cytolytic T cell reagents: A study using HLA loss mutant lymphoblastoid cell lines and monoclonal antibodies detecting the HLA-DP product(s). <i>Human Immunology</i> , 1985, 13, 21-32.	2.4	12
112	Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine. <i>Cancer Gene Therapy</i> , 2002, 9, 243-253.	4.6	12
113	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. <i>Targeted Oncology</i> , 2018, 13, 567-582.	3.6	12
114	Inhibition of anti-class I cytotoxicity by anti-class II monoclonal antibodies (MoAb). II. Blocking of anti-class I CTL clones by anti-DR MoAb. <i>Human Immunology</i> , 1985, 13, 139-143.	2.4	11
115	Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. <i>Haematologica</i> , 2003, 88, 1396-404.	3.5	11
116	N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma. <i>Melanoma Research</i> , 1994, 4, 11-19.	1.2	10
117	Intralesional Selection of T Cell Clonotypes in the Immune Response to Melanoma Antigens Occurring During Vaccination. <i>Journal of Immunotherapy</i> , 1998, 21, 198-204.	2.4	10
118	Use of the Vdelta1 Variable Region in the Functional T-Cell Receptor alpha Chain of a WT31+ Cytotoxic T Lymphocyte Clone which Specifically Recognizes HLA-A2 Molecule. <i>Scandinavian Journal of Immunology</i> , 1992, 35, 487-494.	2.7	9
119	Genetic and molecular analyses of lymphocyte-defined HLA-D region specificities. <i>Human Immunology</i> , 1983, 8, 25-32.	2.4	8
120	Multiple VLA antigens on a subset of melanoma clones. <i>Human Immunology</i> , 1990, 28, 119-122.	2.4	8
121	??1-Integrins on Melanoma Clones Regulate the Interaction with Autologous Cytolytic T-Cell Clones. <i>Journal of Immunotherapy</i> , 1992, 12, 183-186.	2.4	8
122	New tumour-restricted melanoma antigens as defined by cytotoxic T-cell responses. <i>Melanoma Research</i> , 1997, 7, S99.	1.2	8
123	Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. <i>Tissue Antigens</i> , 2002, 59, 273-279.	1.0	8
124	T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e783-e788.	1.6	8
125	HLA-Dw/LD directed cytotoxic T cell clones. <i>Human Immunology</i> , 1984, 10, 153-164.	2.4	7
126	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2514.	4.8	7

#	ARTICLE	IF	CITATIONS
127	Inhibition of Anti-class I cytotoxicity by anti-class II monoclonal antibodies (MoAb). I. Blocking of bulk non-DR and non-DQ-directed cytotoxic T cells by MoAb against DR, DO, and DP. <i>Human Immunology</i> , 1985, 13, 125-137.	2.4	6
128	Progress in Understanding Complexity and Determinants of Immune-Related Prognostic Subsets in Primary Melanoma. <i>Cancer Research</i> , 2019, 79, 2457-2459.	0.9	6
129	Expansion of Major Histocompatibility Complex-Restricted Antimelanoma Cytotoxic T-Cell Lymphocyte Clones with Identical T-Cell Receptor from Tumor-Infiltrating Lymphocytes. <i>Journal of Immunotherapy</i> , 1992, 12, 207-211.	2.4	5
130	Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2021, 10, 1741.	2.4	5
131	Expansion of Immunostimulatory Dendritic Cells from Peripheral Blood of Patients with Cancer. <i>Oncologist</i> , 1997, 2, 65-69.	3.7	5
132	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.		4
133	Immune response to specific human tumors. <i>Current Opinion in Immunology</i> , 1989, 1, 917-921.	5.5	3
134	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 240.	8.6	3
135	Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 628324.	2.8	2
136	Cancer Immunotherapy: from the lab to clinical applications. Potential impact on cancer centresâ€™ organisation. <i>Ecancermedalscience</i> , 2016, 10, 691.	1.1	1
137	Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum. <i>European Urology</i> , 2018, 73, 153-155.	1.9	1
138	Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis. <i>Cancers</i> , 2020, 12, 1828.	3.7	1
139	Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine. , 0, .		1
140	Melanoma: The Milan Melanoma Cell Lines. , 2002, , 283-292.		1
141	Stem Cells Research: Impact on Molecular Biology of Cancer and Prospects for Therapy of Neoplastic Diseases. <i>Tumori</i> , 2000, 86, 375-380.	1.1	0
142	Artificial Antigen Presenting Cells With Preclustered anti-CD28/-CD3/-LFA-1 Monoclonal Antibodies Are Highly Effective To Induce The Ex-Vivo Expansion Of Functional Human Antitumor T Cells. <i>Nature Precedings</i> , 2007, , .	0.1	0
143	APAF-1 Signaling. , 2011, , 231-234.		0
144	APAF-1 Signaling. , 2014, , 315-319.		0